Biological and Clinical Markers in Panic Disorder

Area of Science:

• Neuroscience
• Psychiatry
• Biomarker Research

Background:

• Objective classification of mental disorders aids in understanding etiology, diagnosis, risk assessment, severity determination, and prognosis.
• Panic disorder (PD) lacks definitive objective markers, hindering precise clinical management.

Purpose of the Study:

• To review existing biological and clinical markers for panic disorder (PD).
• To explore potential biomarkers for improved diagnosis and understanding of PD.

Main Methods:

• Comprehensive literature search of PubMed and Science Direct using keywords related to panic disorder biomarkers and neurobiology.
• Inclusion of English-language, peer-reviewed articles and inspection of reference lists.

Main Results:

• Potential biomarkers include structural amygdala/hippocampus changes, altered cerebral blood flow, serotonin and noradrenergic system activation, respiratory and heart rate variability, blood cell markers, and HPA axis dysregulation.
• A clinical staging model for PD was identified: prodromal (stage 1), acute (stage 2), panic attacks (stage 3), and chronic (stage 4).

Conclusions:

• The clinical utility, sensitivity, specificity, and predictive value of current PD biomarkers remain uncertain.
• A proposed staging model for PD shows potential as a valid marker for susceptibility, diagnosis, prognosis, and prediction.
• A longitudinal model integrating biological and clinical markers for PD is suggested.